Australia at risk of falling behind USA and Europe in preventing deadly recurrence of Melanoma

Australia at risk of falling behind USA and Europe in preventing deadly recurrence of Melanoma

23 August 2019

Federal government urged to provide certainty of access to immunotherapy for high risk melanoma patients.

Melanoma Institute Australia is urging the federal government to undertake a timely and efficient review of an immunotherapy treatment effective in preventing the deadly spread of melanoma, and fast track its listing on the Pharmaceutical Benefits Scheme (PBS). 

Immunotherapy nivolumab was one of three treatments for resected Stage III metastatic melanoma submitted to the Pharmaceutical Benefits Advisory Committee (PBAC) for consideration for PBS listing. 

All three treatments are effective in preventing melanoma recurrence and its spread to other organs including the brain, lungs and liver. Immunotherapy nivolumab is effective for the majority of these high risk patients.

This afternoon the federal government announced nivolumab had been deferred for further consideration, while a targeted combination therapy (effective for less than half these patients) was approved and a third treatment was rejected.

Co-Medical Directors of Melanoma Institute Australia, Professor Georgina Long and Professor Richard Scolyer, said whilst they were very pleased to see one treatment listed, they were disappointed for the majority of high risk melanoma patients that the immunotherapy treatment was not.

‘It is a sad irony that Australia has the highest melanoma rates in the world, yet we risk falling behind the USA and many European countries where this immunotherapy preventing melanoma recurrence in the majority of these high risk patients is already available and subsidised,’ said Professor Georgina Long.

‘Australian patients would like certainty that they will be able to access affordable immunotherapy treatment which has proven successful in clinical trials and which many hundreds of patients have been forced to access on compassionate grounds or face costs of tens of thousands of dollars,’ she said. 

One Australian dies from melanoma every five hours. Melanoma Institute Australia is leading global efforts to find effective treatments for all melanoma patients, and eventually reach zero deaths from melanoma. 

‘It is frustrating, disheartening and disappointing for Australia to be leading the international melanoma research effort, yet our own government is lagging behind the rest of the world in ensuring high risk patients have subsidised access to this proven immunotherapy treatment,’ Professor Scolyer added. 

‘We urge the federal governent to fast track further consideration of this immunotherapy and remain hopeful it will eventually be listed on the PBS,’ he said.

Australasian Melanoma Conference AMC2021
19 Nov - 20 Nov 2021

Australasian Melanoma Conference AMC2021

The 2021 Australasian Melanoma Conference (AMC2021) will held in Sydney, Australia.

Australian researchers spearhead paradigm shift in melanoma treatment
20 Sep 2021

Australian researchers spearhead paradigm shift in melanoma treatment

Drug therapy set to become standard treatment in high-risk early stage patients to stop disease spread

Tags: melanoma
Prof Georgina Long AO awarded inaugural Outstanding Female Researcher Medal from AAHMS
16 Sep 2021

Prof Georgina Long AO awarded inaugural Outstanding Female Researcher Medal from AAHMS

Prof Long AO has been recognised by Australian Academy of Health and Medical Sciences for her transformative work advancing melanoma treatments.

Tags: melanoma
Amie St Clair Ball in Wagga postponed for a third time
06 Sep 2021

Amie St Clair Ball in Wagga postponed for a third time

COVID restrictions continue to impact fundraising for melanoma services in Riverina.

Honouring Ben's life by supporting the next generation of melanoma researchers
30 Aug 2021

Honouring Ben's life by supporting the next generation of melanoma researchers

Ben Garrow lost his life to melanoma. In his honour his family has established a scholarship to support a PhD student whose work focuses on saving lives from melanoma.

MIA's annual Research Retreat 2021
20 Aug 2021

MIA's annual Research Retreat 2021

More than 150 clinicians, researchers and MIA staff gathered online to share research highlights.

Understanding the needs of Stage III melanoma patients when choosing treatments.
28 Jul 2021

Understanding the needs of Stage III melanoma patients when choosing treatments.

Independent researchers at The University of Sydney are seeking patient feedback.

Community Fundraising Wrap Up Apr-June 2021
21 Jul 2021

Community Fundraising Wrap Up Apr-June 2021

A re-cap of the wonderful, and often very creative, community fundraising initiatives over the April to June quarter.

Tags: melanoma
Patients paying it forward
19 Jul 2021

Patients paying it forward

Our patients who donate their tissue samples and records to our research are helping to make a difference to the lives of future melanoma patients. 

Tags: melanoma
Research boost to improve outcomes for melanoma patients
15 Jul 2021

Research boost to improve outcomes for melanoma patients

MIA researchers have recently been awarded two competitive funding grants, which will help facilitate their ground-breaking work in melanoma research.

Tags: melanoma
Amie St Clair 10th Annual Ball
25 Jun 2022

Amie St Clair 10th Annual Ball

Celebrate the 10th anniversary of Amie St Clair Melanoma at the Annual Ball in Wagga Wagga!   

Riverina Melanoma Ride
31 Mar - 07 Apr 2022

Riverina Melanoma Ride

Postponed to early 2022. Melanoma survivor Matt Kean is doing a 1000km bike ride around the Riverina to increase awareness of melanoma and raise funds for Amie St Clair Melanoma - MIA. There are many ways you can be part of this life-changing ride!

Melanoma Clinical Trial opens in Wagga
23 Jun 2021

Melanoma Clinical Trial to open in Wagga

Riverina patients gain access to potentially life saving immunotherapy treatment close to home.

Tags: melanoma
Queen's Birthday Honour for Professor Richard Scolyer
13 Jun 2021

 Queen's Birthday Honour for Professor Richard Scolyer

MIA's Prof Scolyer has been appointed as an Officer (AO) of the Order of Australia. 

Tags: melanoma
Sharing our research on the global stage at 2021 ASCO Annual Meeting
07 Jun 2021

Sharing our research on the global stage at 2021 ASCO Annual Meeting

Research from MIA was once again in the spotlight as findings were shared at the virtual ASCO21. 

Tags: melanoma
Australian researchers lead world in successful trial of new cancer treatment
03 Jun 2021

Australian researchers lead world in successful trial of new cancer treatment.

In a breakthrough which could extend to the treatment of other cancers, a new immune checkpoint inhibitor has proven effective in helping save the lives of advanced melanoma patients.

Tags: melanoma
Thank you doesn't seem enough for our melanoma nurses.
28 May 2021

Thank you doesn't seem enough for our melanoma nurses.

Whilst our research and clinical teams are trialling new treatments to save lives, it is our nurses who are on the front line providing care and support.

Tags: melanoma
Sharing our knowledge of melanoma on the global stage
20 Apr 2021

Sharing our knowledge of melanoma on the global stage

As leaders in the field of melanoma, clinicians and researchers from MIA shared their knowledge at the virtual 10th World Congress of Melanoma. 

Tags: melanoma
Community Fundraising Wrap Up Jan-Mar 2021
15 Apr 2021

Community Fundraising Wrap Up Jan-Mar 2021

The easing of COVID restrictions has meant the return of community events, and we recognise the generous support of our community fundraisers.

Tags: melanoma
Melanoma patients and their families urged to speak up and put national spotlight on melanoma.
15 Apr 2021

Melanoma patients and their families urged to speak up and put national spotlight on melanoma.

Melanoma patients and their carers are being urged to participate in a ground-breaking survey which will shape the future of melanoma treatment, research, support and funding in Australia.

Tags: melanoma